| Exhibit No. | | | Description | | |
| | | | | |
| | | | | |
| 10.1 | | | Amendment No. 1, dated as of October 20, 2022, among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., and IDEXX Laboratories GmbH, as borrowers (collectively, “Borrowers”), the lenders, JPMorgan Chase Bank, N.A., as administrative agent (“Agent”), JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto, to Fourth Amended and Restated Credit Agreement, dated as of December 9, 2021, among the Borrowers, the lenders, the Agent, and the other parties thereto (filed as Exhibit 10.1 to Current Report on Form 8-K filed October 21, 2022, File No. 0-19271, and incorporated herein by reference). | | |
| | | | | |
| 31.1 | | | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | |
| | | | | |
| 31.2 | | | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | |
| | | | | |
| 32.1 | | | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | |
| | | | | |
| 32.2 | | | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | |
| | | | | |
| 101 | | | The following financial and related information from IDEXX Laboratories, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline eXtensible Business Reportable Language (iXBRL) includes: (i) the Condensed Consolidated Balance Sheet; (ii) the Condensed Consolidated Statement of Income; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statement of Changes in Stockholders' Equity; (v) the Condensed Consolidated Statement of Cash Flows; and, (vi) Notes to Consolidated Financial Statements. | | |
| | | | | |
| 104 | | | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL and contained in Exhibit 101. | | |
| | | | | |
| | | | | |
filings.tools